NCT03312738
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes: Must have ER+ tumor(s)
Exclusions: Male patients
https://ClinicalTrials.gov/show/NCT03312738